Trostberg, December 4, 2025 – Alzchem Group AG approved a comprehensive investment program for further capacity expansion in creatine products. The focus is particularly on the application areas of health, nutrition, and pharmaceuticals. In total, around 120 million euros will be invested in the construction of a new, increasingly automated production facility for creatine and its precursors, as well as in the upstream infrastructure. Commissioning is planned to take place in stages starting from the second half of 2027. Alzchem sees this investment as offering additional annual sales potential in the low triple-digit million euro range, with correspondingly positive contributions to earnings.